Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | CCR2 | P41597 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134824 | 0.89 | HRH1 (0.48) | HRH1ADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL6198682 | 0.86 | HRH1 (0.47) | HRH1ADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL6134968 | 0.85 | MAOB (0.47) | HRH1ADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL4652204 | 0.84 | DRD2 (0.63) | DRD2LMNAALDH1A1MAPT | |
| SCHEMBL63533 | 0.83 | SLC18A3 (0.53) | HRH1HRH3DRD2MCHR1LMNA | |
| SCHEMBL13436309 | 0.83 | MCHR1 (0.58) | HRH1ADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL63749 | 0.81 | KDM4E (0.51) | DRD2MCHR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL63894 | 0.80 | HDAC3 (0.54) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL28177768 | 0.79 | ALDH1A1 (0.46) | DRD2LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL6134946 | 0.79 | DGAT1 (0.44) | HRH1ADRA1DADRA1AADRA1BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | HRH1 1307/4885ADRA1D 1963/4885ADRA1A 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.